Exciting news from our youngest spinoff company: Engimmune Therapeutics completed a CHF 15.5 million seed financing round to boost R&D of novel T-cell receptor (TCR)-based therapeutics. Proceeds from the financing will be used to further build Engimmune’s pipeline, expand the research team in Switzerland and build a foothold in Denmark, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.
The startup community is hit particularly hard by the global COVID-19 pandemic. The D-BSSE spinoff deepCDR Biologics is making the best out of this extraordinary situation - and realises that the pandemic provides the perfect platform to showcase the deepCDR technology and antibody discovery and development. Interview with the co-founder Derek Mason.
The Botnar Research Centre for Child Health (BRCCH) announces its first four multi-investigator projects and thus the start of its research activities. D-BSSE professor Randall Platt will have the lead of a project which aims to develop a CRISPR-based technology involving engineered bacteria which are capable of sensing, remembering, and reporting on the environment within the gut.